Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | PS-1145 | IKK | NFKB | 0.00485 | uM | 7477.065 | 1.4055 | 2.0786 | 0.7891 | |
| SUM185PE | TNBC | Luminal | Afatinib | EGFR/HER2 | ErbB | 0.107 | uM | 12269.165 | 1.4070 | 2.5333 | 0.6001 | |
| LY2 | HR+ | Luminal | Tozasertib | AURK/FLT3/ABL/JAK2 | AURK | 0.000427 | uM | 10816.15 | 1.4082 | 5.1867 | 0.3031 | |
| MCF7 | HR+ | Luminal | Ixabepilone | TUBB | TUBB | 0.0631 | uM | 7492.095 | 1.4088 | 1.7994 | 1.0194 | |
| SUM185PE | TNBC | Luminal | 5-DFUR | TYMS | TYMS | 0.064 | uM | 12269.143 | 1.4088 | 5.0690 | 0.3088 | |
| MDA-MB-231 | TNBC | Basal B | Vorinostat | HDAC | HDAC | 30 | uM | 7504.065 | 1.4103 | 1.4722 | 1.6220 | |
| HCC1806 | TNBC | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7450.084 | 1.4104 | 1.3161 | 2.3432 | |
| Hs 578T | TNBC | Basal B | Nutlin 3a | MDM2 | MDM2 | 0.533 | uM | 7473.066 | 1.4109 | 1.3143 | 2.3582 | |
| MB 157 | Unknown | Unknown | AG1024 | IGF1R | RTK | 33.3 | uM | 7482.066 | 1.4115 | 1.7098 | 1.1347 | |
| MDA-MB-415 | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 33.3 | uM | 10938.072 | 1.4119 | 2.6980 | 0.5611 | |
| Hs 578T | TNBC | Basal B | Baicalein | Lipoxygenase | Metabolism | 1.33 | uM | 7472.072 | 1.4122 | 1.6497 | 1.2269 | |
| MCF 10F | NM | - | CPT-11 | TOP1 | TOP | 0.00472 | uM | 7872.007 | 1.4125 | 1.4468 | 1.7126 | |
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7794.018 | 1.4132 | 1.4568 | 1.6812 | |
| LY2 | HR+ | Luminal | L-779450 | BRAF | MAPK | 33.3 | uM | 10816.149 | 1.4146 | 3.2899 | 0.4545 | |
| AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 0.137 | uM | 7794.018 | 1.4160 | 1.4598 | 1.6812 | |
| MDA-MB-436 | TNBC | Basal B | Oxaliplatin | DNA cross-linker | DNA cross-linker | 1.01 | uM | 7900.011 | 1.4160 | 2.5791 | 0.5977 | |
| Hs 578T | TNBC | Basal B | Ispinesib | KSP | Kinesin | 0.0000853 | uM | 7474.067 | 1.4169 | 1.2708 | 2.7442 | |
| Hs 578T | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7473.084 | 1.4170 | 1.3739 | 2.0337 | |
| SUM185PE | TNBC | Luminal | Valproic acid | HDAC | HDAC | 4.8 | uM | 12269.143 | 1.4179 | 5.1973 | 0.3088 | |
| Hs 578T | TNBC | Basal B | Triciribine | AKT | AKT | 6.67 | uM | 7473.074 | 1.4185 | 1.2956 | 2.5364 | |
| MDA-MB-436 | TNBC | Basal B | LY294002 | PI3K | PI3K | 0.000256 | uM | 7898.029 | 1.4188 | 2.2667 | 0.7130 | |
| MDA-MB-468 | TNBC | Basal A | Cisplatin | DNA cross-linker | DNA cross-linker | 0.016 | uM | 7906.017 | 1.4197 | 4.0035 | 0.3822 | |
| MDA-MB-468 | TNBC | Basal A | 17-AAG | HSP90 | HSP90 | 0.00128 | uM | 7909.05 | 1.4198 | 1.7179 | 1.1429 | |
| Hs 578T | TNBC | Basal B | GSK1838705A | IGF1R | RTK | 0.000171 | uM | 7472.098 | 1.4217 | 1.5249 | 1.5098 | |
| MDA-MB-468 | TNBC | Basal A | Gemcitabine | DNA replication | DNA replication | 0.00925 | uM | 7906.011 | 1.4237 | 2.1403 | 0.7830 |